A study in the Dec. 15 issue of the Journal of Clinical Sleep Medicine indicates that significant associations exist between parent-reported insomnia symptoms and medical complaints of gastrointestinal regurgitation and headaches in young school-aged children. Results of multivariate regression analysis show that parent-reported insomnia was 3.3 times more likely in children with gastrointestinal regurgitation and 2.3 times more likely in children with headaches. Nineteen percent of children met the criteria for insomnia, which was defined as often having trouble falling asleep and/or waking up often in the night. Gastrointestinal regurgitation was reported in 7.
The gastric cardiac adenocarcinoma (GCA) is a very rare disease. In recent decades, however, the incidence of the GCA has increased dramatically in many Western countries. An increasing trend in GCA is also observed in municipal regions but not in rural regions of China. Another striking feature is the strong male predominance among patients with GCA. Some of the reasons above are still unclear and require further epidemiological investigations. A research article published on November 21, 2009 in the World Journal of Gastroenterology addresses this problem. A research team from Taiwan investigated the etiologic factors shared by lifestyles, diet, and other environmental exposures associated with GCA among men in Taiwan.
Ghrelin, a hormone produced in the stomach, may be used to boost resistance to, or slow, the development of Parkinson's disease, Yale School of Medicine researchers report in a study published in a recent issue of the Journal of Neuroscience. Parkinson's disease is caused by a degeneration of dopamine neurons in an area of the midbrain known as the substantia nigra, which is responsible for dopamine production. Reduced production of dopamine in late-stage Parkinson's causes symptoms such as severe difficulty in walking, restricted movements, delays in moving, lack of appetite, difficulty eating, periods of remaining motionless (known as "freezing") and head and limb tremors.
GlaxoSmithKline (GSK) announced that it has filed its vaccine for the prevention of rotavirus gastroenteritis (approved as Rotarix ® in a number of countries outside of Japan). The candidate vaccine, which is given orally, is the first to be filed for approval for the prevention of rotavirus gastroenteritis in infants in Japan. Rotavirus infection is the leading cause of severe acute gastroenteritis in infants. GlaxoSmithKline one of the world's leading research-based pharmaceutical and healthcare companies is committed to improving the quality of human life by enabling people to do more, feel better and live longer. Cautionary statement regarding forward-looking statements Under the safe harbor provisions of the U.
New research published in the December issue of the Journal of the American College of Surgeons finds that the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) is a powerful tool for assessing outcomes of uncommon, high-risk surgical procedures, including pancreatic necrosectomy. This is the first time that national data on this particular procedure has been available and analyzed, and the data from ACS NSQIP showed that patients undergoing pancreatic necrosectomy had better outcomes than predicted. Necrotizing pancreatitis is the most severe form of acute pancreatitis, an infection or inflammation of the pancreas.
Amneal Receives FDA Approval For Nizatidine Oral Solution, The First Generic Oral Solution For Axid R In The Market
Amneal Pharmaceuticals is pleased to announce that it has received U.S. FDA approval to manufacture Nizatidine Oral Solution in the 15 mg/mL strength effective November 18, 2009. It is an AA-rated, therapeutically equivalent alternative to Axid® Oral Solution (a licensed trademark of Braintree Labs). Nizatidine Oral Solution is the first available generic in oral solution form and marks Amneal's fourth liquid approval. It represents the company's first exclusive generic - Amneal has 180-day exclusivity to market the product beginning from the date of first shipment. Amneal will sell Nizatidine Oral Solution, a clear yellow, peppermint-flavored syrup, in a 16 fl oz/473 mL lightweight, UV-protected plastic bottle.